<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Risk factors for adverse outcomes after ST-elevation myocardial infarction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Risk factors for adverse outcomes after ST-elevation myocardial infarction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Risk factors for adverse outcomes after ST-elevation myocardial infarction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph S Alpert, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter WF Wilson, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Simons, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey A Breall, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pamela S Douglas, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia A Pellikka, MD, FACC, FAHA, FASE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Juan Carlos Kaski, DSc, MD, DM (Hons), FRCP, FESC, FACC, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Cannon, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan S Jaffe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H459616532"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with ST-elevation myocardial infarction (STEMI) should undergo risk stratification soon after presentation. This process has two components:</p><p class="bulletIndent1"><span class="glyph">●</span>Early in-hospital identification of patients at increased risk for recurrent ischemic events.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identification of patients after a myocardial infarction (MI) who are at increased risk for arrhythmic or nonarrhythmic death.</p><p></p><p>The individual risk factors that influence prognosis will be discussed here. The use of these risk factors in risk prediction models and the prognosis of patients after MI are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction", section on 'Early risk stratification'</a> and  <a class="medical medical_review" href="/z/d/html/1531.html" rel="external">"Prognosis after myocardial infarction"</a>.)</p><p>Although there is significant overlap in the risk factors for acute non-ST-elevation coronary syndrome (NSTEACS) and STEMI, they are presented separately, in part because the risk prediction models for STEMI and NSTEACS differ in their components. (See  <a class="medical medical_review" href="/z/d/html/77.html" rel="external">"Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes"</a>.)</p><p class="headingAnchor" id="H459617392"><span class="h1">FACTORS PRESENT BEFORE MI</span></p><p class="headingAnchor" id="H459619117"><span class="h2">Number of CHD risk factors</span><span class="headingEndMark"> — </span>The four modifiable coronary heart disease (CHD) risk factors (hypertension, smoking, dyslipidemia, and diabetes), as well as a family history of premature CHD, predict the development of atherosclerosis and its clinical consequences (including STEMI) in a high percentage of patients. (See  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease", section on 'Established risk factors for atherosclerotic CVD'</a>.)</p><p>The relationship between the number of these risk factors and in-hospital mortality was evaluated in a study of 542,008 patients with first MI and without prior cardiovascular disease from the National (United States) Registry of Myocardial Infarction (NRMI) [<a href="#rid1">1</a>]. Over 85 percent of patients had at least one CHD risk factor. After adjustment for age and other clinical risk factors, there was a statistically significant inverse increase in risk between the number of CHD risk factors and in-hospital mortality (odds ratios of 1.54, 1.39, 1.30, 1.10, 1.09, and 1.00 with 0, 1, 2, 3, 4, and 5 risk factors, respectively). The explanation for this surprising finding is unknown. Patients who continue to smoke after an MI are at particularly high risk for recurrent MI and/or death.</p><p class="headingAnchor" id="H459619187"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>Patients with chronic renal failure as well as those with end-stage kidney disease have a higher risk for and a worse outcome after MI. (See  <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a> and  <a class="medical medical_review" href="/z/d/html/1960.html" rel="external">"Risk factors and epidemiology of coronary heart disease in end-stage kidney disease (dialysis)"</a>.)</p><p>The magnitude of this effect has been examined in several studies [<a href="#rid2">2-5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a review of over 130,000 older adults hospitalized with an acute MI, the one-year mortality was 24, 46, and 66 percent in patients with a serum creatinine of &lt;1.5, 1.5 to 2.4, and 2.5 to 3.9 mg/dL (&lt;132, 132 to 212, and 221 to 345 micromol/L), respectively [<a href="#rid2">2</a>]. After adjustment for patient and treatment characteristics, the hazard ratios for mild and moderate renal insufficiency were greatest at one month and gradually declined, no longer being significant at one year.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar observations were made in an analysis from the VALIANT trial of 14,527 patients with an acute MI (two-thirds with STEMI) complicated by heart failure (HF), left ventricular (LV) dysfunction, or both [<a href="#rid3">3</a>]. At three years, the mortality rates for patients with an estimated glomerular filtration rate (GFR) of ≥75, 60 to 74.9, 45 to 59.9, and &lt;45 mL/min per 1.73 m<sup>2</sup> were 14.1, 20.5, 28.9, and 45.5 percent. After adjustment for other risk factors, the risk of death or nonfatal cardiovascular complications increased significantly with declining GFR (hazard ratio 1.10 for each 10-unit decrease in GFR below 81.0 mL/min per 1.73 m<sup>2</sup>).</p><p></p><p>A potential limitation of these studies is that only baseline serum creatine values were used. This can be a source of error because the formulas used for calculation of the creatinine clearance and the estimated GFR require stable values over time, which might not be present in patients with an acute coronary syndrome. (See  <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">"Assessment of kidney function"</a>.)</p><p class="headingAnchor" id="H459619349"><span class="h2">Peripheral artery disease</span><span class="headingEndMark"> — </span>The presence of intermittent claudication appears to predict worse outcomes in patients with an STEMI. This was illustrated in a study of 1045 patients (52 percent with a known STEMI) evaluated two months after an acute MI in which 78 (7 percent) had intermittent claudication [<a href="#rid6">6</a>]. At 26 months of follow-up, those with claudication were five times more likely to have a fatal cardiac event than those without claudication (19.2 versus 3.6 percent). The patients with claudication were older and more likely to have a history of diabetes, a prior MI, a stroke, or diminished LV function. Even when these comorbidities were taken into account, patients with claudication had a significantly higher incidence of cardiac death (hazard ratio 6.57).</p><p class="headingAnchor" id="H3527271729"><span class="h2">Low BMI</span><span class="headingEndMark"> — </span>Multiple studies have identified low body mass index (BMI) as a predictor of poor outcome after MI. As an example, a cohort study of over 57,000 patients with MI found that underweight patients had a significant 13 percent higher adjusted risk of 30-day death [<a href="#rid7">7</a>], possibly as the result of concomitant frailty. This increased risk persisted as long as 17 years.</p><p class="headingAnchor" id="H459617406"><span class="h1">HEART FAILURE</span><span class="headingEndMark"> — </span>Evidence of HF on physical examination or chest radiograph on hospital arrival indicates extensive LV systolic and/or diastolic dysfunction and is associated with a worse prognosis compared with no pulmonary congestion [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H459617413"><span class="h2">Killip class</span><span class="headingEndMark"> — </span>The Killip classification categorizes patients with an acute MI based upon the presence or absence of simple physical examination findings that suggest LV dysfunction  (<a class="graphic graphic_table graphicRef65592" href="/z/d/graphic/65592.html" rel="external">table 1</a>) [<a href="#rid9">9</a>]. Patients presenting with Killip class II or III HF complicating an acute MI tend to be older and are more often female; they also have higher rates of comorbidities, including hypertension and diabetes [<a href="#rid10">10,11</a>]. Patients with HF are also less likely to receive therapies of known efficacy in acute MI, including <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, heparin, beta blockers, statins, fibrinolytic agents, and angioplasty, despite evidence that these therapies are beneficial in this patient subset [<a href="#rid10">10,11</a>].</p><p>The higher the Killip class on presentation, the greater the subsequent mortality [<a href="#rid8">8-17</a>]. A study from the Second National Registry of Myocardial Infarction (NRMI-2) included 190,518 patients with acute MI, of whom 36,303 (19 percent) had Killip class II or III HF on admission [<a href="#rid10">10</a>]. These patients had a significantly higher in-hospital mortality than those without HF (21.4 versus 7.2 percent). Similar findings were noted in an analysis of international data on 4830 patients with STEMI from the GRACE registry [<a href="#rid11">11</a>]. Sixteen percent had Killip class II or III HF on admission; patients with HF had increased mortality in-hospital (17 versus 4 percent) as well as from discharge to six months (20 versus 3 percent). In this report, HF developing after admission was associated with an even higher in-hospital mortality (18 percent).</p><p>The Killip class is prognostically important in patients who undergo fibrinolysis [<a href="#rid8">8,12,13</a>] or primary percutaneous coronary intervention (PCI) (angioplasty with or without stenting) [<a href="#rid14">14-17</a>]. In one series of 1548 patients undergoing primary angioplasty, increasing Killip class was associated with increasing mortality at one year, an association that appears to have been due to a higher incidence of suboptimal myocardial perfusion [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/81.html" rel="external">"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST-elevation myocardial infarction"</a>.)</p><p class="headingAnchor" id="H459617420"><span class="h2">Hypotension</span><span class="headingEndMark"> — </span>Hypotension (systolic pressure &lt;100 mmHg) or frank shock is associated with a poor prognosis. This is especially true in the patient with an anterior MI in whom hypotension is the result of extensive myocardial damage and markedly reduced LV ejection fraction (LVEF) [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/44.html" rel="external">"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction"</a>.)</p><p>In comparison, hypotension in the presence of an inferior MI may be the result of increased vagal activity, the so-called Bezold-Jarisch reflex. This tends to be a transient phenomenon that is often reversed with <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> and/or intravenous volume administration. The prognosis for these patients is usually good.</p><p class="headingAnchor" id="H459617427"><span class="h2">Tachycardia</span><span class="headingEndMark"> — </span>Although heart rate may be elevated soon after the patient arrives in the CCU, heart rate usually declines thereafter to a level that reflects the degree of activation of the sympathetic nervous system. Patients with sustained heart rates &gt;90 beats/min usually have larger and more often anterior infarcts, marked impairment of LV function, and therefore a poor prognosis [<a href="#rid8">8,18</a>]. (See  <a class="medical medical_review" href="/z/d/html/1074.html" rel="external">"Sinus tachycardia: Evaluation and management", section on 'Management in patients with acute coronary syndrome'</a>.)</p><p class="headingAnchor" id="H459617434"><span class="h1">ELECTROCARDIOGRAM</span><span class="headingEndMark"> — </span>Worse outcomes after STEMI are seen with the following electrocardiogram (ECG) findings, which usually indicate a larger infarction:</p><p class="bulletIndent1"><span class="glyph">●</span>Anterior compared to inferior infarcts</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of Q waves</p><p class="bulletIndent1"><span class="glyph">●</span>A greater number of leads showing ST elevation</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of ST elevation resolution at 90 to 180 minutes after fibrinolysis or of ST depression in leads without ST elevation</p><p></p><p>The prognostic role of the ECG is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2110.html" rel="external">"Electrocardiogram in the prognosis of myocardial infarction or unstable angina"</a>.)</p><p class="headingAnchor" id="H2800714153"><span class="h1">CONDUCTION SYSTEM DISEASE</span><span class="headingEndMark"> — </span>New left bundle branch block or atrioventricular block after acute MI are associated with worse outcomes. These occur less often with active reperfusion. (See  <a class="medical medical_review" href="/z/d/html/45.html" rel="external">"Conduction abnormalities after myocardial infarction", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H459617441"><span class="h1">ATRIAL FIBRILLATION</span><span class="headingEndMark"> — </span>Atrial fibrillation (AF) is the most common supraventricular arrhythmia after an MI and its development at any time is associated with increased mortality. The reported incidence of new onset (no prior history) AF within 48 hours of MI is 6.7 to 7.8 percent in large series [<a href="#rid19">19</a>]. The discussion of AF developing shortly after MI is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/82.html" rel="external">"Supraventricular arrhythmias after myocardial infarction", section on 'Atrial fibrillation'</a>.)</p><p>The best available information on the relationship between AF and long-term mortality after MI comes from a community-based study of 3220 patients with first MI cared for between 1983 and 2007 [<a href="#rid20">20</a>]. AF developed in 729 (218 within two days, 119 between days 3 and 30, and 392 after 30 days) with a cumulative incidence of 19 percent at five years (incidence rate of 42 per 1000 person-years). During a mean follow-up of 6.6 years, the development of AF was independently associated with an increased risk of death (hazard ratio [HR] 3.77, 95% CI 3.37-4.21). The magnitude of this risk was associated with the time of development of AF (HR 1.63 for AF within two days, 1.81 for AF between 3 and 30 days, and 2.58 for AF &gt;30 days). An increased risk of long-term mortality was also noted in a study of more than 2300 patients with acute coronary syndrome (37 percent with STEMI; 19 percent with AF) cared for between 1995 and 2001 [<a href="#rid21">21</a>]. The risk of all-cause mortality was increased significantly at 10 years.</p><p class="headingAnchor" id="H459617448"><span class="h1">VENTRICULAR ARRHYTHMIAS</span><span class="headingEndMark"> — </span>The occurrence of ventricular tachycardia (VT) in the peri-MI period (ie, within the first 48 hours after the MI) is presumably due to transient ischemia. The prognosis after either early VT or ventricular fibrillation (VF) is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features", section on 'Prognosis after early VF'</a>.)</p><p class="headingAnchor" id="H459617455"><span class="h1">RECURRENT ISCHEMIA</span><span class="headingEndMark"> — </span>Recurrent ischemia, either symptomatic (ie, angina at rest or with minimal exertion) or silent, markedly worsens the prognosis [<a href="#rid22">22-26</a>]. The following observations from GUSTO-I and GUSTO-IIb illustrate the range of findings.</p><p>The GUSTO-I trial evaluated 40,484 patients with a STEMI who were treated with fibrinolysis. Recurrent ischemia occurred in 8131 patients (20 percent), including 4488 who had angina only, 3021 with angina and ST segment changes, 337 with angina and hemodynamic abnormalities, and 285 patients with angina, ST segment changes, and hemodynamic abnormalities [<a href="#rid22">22</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with recurrent ischemia were more often female, had more cardiovascular risk factors, less often received intravenous heparin, and had more extensive and severe coronary disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 30-day reinfarction rate was higher in patients with recurrent ischemia, particularly when associated with ST segment changes or hemodynamic abnormalities  (<a class="graphic graphic_figure graphicRef51228" href="/z/d/graphic/51228.html" rel="external">figure 1</a>). In comparison, 30-day mortality was higher only in those patients who had hemodynamic abnormalities  (<a class="graphic graphic_figure graphicRef73231" href="/z/d/graphic/73231.html" rel="external">figure 2</a>). This pattern was maintained at one year.</p><p></p><p>Similar findings were noted in the GUSTO-IIb trial, which included 4125 patients with an STEMI: 23 percent had recurrent ischemia, which responded to medical therapy in 78 percent [<a href="#rid23">23</a>]. Compared to those without ischemia, those with responsive or refractory ischemia had a higher rate of reinfarction at 30 days (2.7 versus 11 and 28 percent, respectively) and at six months (4.6 versus 13 and 30 percent, respectively). The patients without ischemia had a lower mortality at 30 days and at one year (9 versus 10.7 and 16.4 percent, respectively).</p><p>A report from the GISSI-3 trial, in which 14 percent of patients had recurrent angina after fibrinolytic therapy, also evaluated the setting and timing of ischemia [<a href="#rid24">24</a>]. Angina occurred at rest in 94 percent of patients; one-third of episodes occurred within 72 hours of the MI and between 6 and 10 AM.</p><p>The clinical features and management of recurrent angina after STEMI are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction", section on 'Recurrent chest pain'</a> and  <a class="medical medical_review" href="/z/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction"</a>.)</p><p>Silent ischemia after STEMI is associated with a two- to four-fold increase in cardiac event rates during follow-up compared to those without evidence of ischemia [<a href="#rid25">25,26</a>]. The management of silent ischemia after STEMI is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1488.html" rel="external">"Silent myocardial ischemia: Epidemiology, diagnosis, treatment, and prognosis", section on 'Revascularization'</a>.)</p><p>A number of biomarkers have been correlated with risk in patients with STEMI.</p><p class="headingAnchor" id="H459617476"><span class="h1">TROPONIN</span><span class="headingEndMark"> — </span>Troponin I (cTnI) and T (cTnT) are regulatory proteins found in cardiac myocytes; they are sensitive and specific markers of myocardial necrosis and elevated levels have prognostic importance. (See  <a class="medical medical_review" href="/z/d/html/86.html" rel="external">"Troponin testing: Clinical use"</a>.)</p><p>The potent prognostic value of elevated troponins, obtained within 24 hours of admission or even three or four days after the MI, has been demonstrated in patients with STEMI, even when a percutaneous coronary intervention is performed [<a href="#rid27">27-30</a>]. The higher the peak level of troponin following acute MI, the worse the prognosis, presumably because this reflects more extensive myocardial necrosis. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/86.html" rel="external">"Troponin testing: Clinical use", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H459617483"><span class="h1">B-TYPE NATRIURETIC PEPTIDE</span><span class="headingEndMark"> — </span>Concentrations of B-type natriuretic peptide (BNP) and N-terminal-pro-BNP (NT pro-BNP) are useful in the diagnosis and prognosis of HF. (See  <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">"Natriuretic peptide measurement in heart failure"</a>.)</p><p>BNP and NT pro-BNP also appear to have predictive value in STEMI [<a href="#rid31">31-37</a>]. Elevated values are associated with increased mortality, even in patients without clinical HF and after adjustment for age and LV ejection fraction [<a href="#rid32">32-36</a>]. It has been suggested that NT pro-BNP drawn within 24 hours of the onset of chest pain is more accurate than the TIMI risk score in predicting mortality at nine months [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction", section on 'TIMI risk score'</a>.)</p><p>The clinical role of BNP and NT pro-BNP in risk stratification in patients with STEMI remains to be determined.</p><p class="headingAnchor" id="H459617497"><span class="h1">SERUM POTASSIUM</span><span class="headingEndMark"> — </span>Studies performed before the routine use of beta blockers, statins, and aggressive antithrombotic therapy, in addition to urgent reperfusion in many patients, demonstrated a relationship between low serum potassium levels and the risk of ventricular arrhythmias. These early studies led to specific recommendations for the serum potassium level in patients with acute MI. (See  <a class="medical medical_review" href="/z/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features", section on 'Ventricular fibrillation'</a>.)</p><p>The relationship between serum potassium level and in-hospital mortality in patients with acute MI and managed with recommended therapies was evaluated in a study of nearly 40,000 patients enrolled in a United States database between 2000 and 2008 [<a href="#rid38">38</a>]. After multivariate analysis, a U-shaped relationship between mean post-admission serum potassium level and in-hospital mortality was found. Using a mean post-admission serum potassium level of 3.5 to &lt;4.0 mEq/L as the reference, the adjusted odds ratio for mortality for those with serum potassium levels of &lt;3.0, 3.0 to &lt;3.5, 4.0 to &lt;4.5, 4.5 to &lt;5.0, 5.0 to &lt;5.5, and ≥5.5 mEq/L were 8.11, 1.45, 1.25, 1.96, 3.27, and 6.44, respectively. It is important to note that patients with a serum potassium between 4.5 and 5.0 mEq/L, a range that has previously considered “within normal limits,” had a nearly twofold greater risk of death compared to those with levels between 3.5 to &lt;4.0 mEq/L. The findings of this study pertaining to the secondary composite outcome of ventricular fibrillation or cardiac arrest are presented separately. The relationship between hyperkalemia and mortality in patients with acute MI was confirmed in a 2016 report [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/1060.html" rel="external">"Ventricular arrhythmias during acute myocardial infarction: Incidence, mechanisms, and clinical features", section on 'Ventricular fibrillation'</a>.)</p><p class="headingAnchor" id="H459617504"><span class="h1">GLYCEMIC CONTROL</span><span class="headingEndMark"> — </span>Patients with diabetes are at increased risk of adverse events after an acute MI compared with patients without diabetes  (<a class="graphic graphic_figure graphicRef80251" href="/z/d/graphic/80251.html" rel="external">figure 3</a>).</p><p class="headingAnchor" id="H459617525"><span class="h1">WHITE BLOOD CELL COUNT</span><span class="headingEndMark"> — </span>Patients with a higher baseline white blood cell (WBC) count, which is a marker of inflammation and the extent of infarction, have an increased risk for an adverse events and short- and long-term mortality after an acute ST elevation [<a href="#rid40">40-45</a>]. In a report from the Cooperative Cardiovascular Project of over 150,000 patients ≥65 years of age with an acute MI (40 percent with ST elevation or left bundle branch block), patients in the highest quintile of WBC were significantly more likely to die at 30 days than those in the lowest quintile (10.3 versus 30.2 percent, adjusted odds ratio 2.37) [<a href="#rid43">43</a>].</p><p>Similar findings were noted in the TIMI 10A and B trials in which the mortality at 30 days was higher in patients with a WBC count &gt;15,000/µL (10.4 versus 0 to 4.9 for a count &lt;15,000 /µL) [<a href="#rid41">41</a>]. In addition, patients with a closed artery at 60 and 90 minutes, those with evidence of thrombus, and those with poorer TIMI myocardial perfusion grades had a significantly higher WBC count than those without these findings [<a href="#rid41">41</a>]. The increase in mortality associated with an elevated baseline WBC persists for as long as 10 months [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H459617532"><span class="h1">ANEMIA</span><span class="headingEndMark"> — </span>The presence of anemia appears to be an adverse predictor of prognosis in patients with a STEMI. In a review of clinical trials that included over 25,000 patients with STEMI, there was an adjusted odds ratio (OR) for cardiovascular mortality at 30 days of 1.21 for each 1 g/dL decline in hemoglobin below 14 g/dL [<a href="#rid46">46</a>]. The risk was also significantly increased (adjusted OR 1.79) in patients with hemoglobin values above 17 g/dL.</p><p>There also may be a graded increase in late (up to 24 months) mortality in patients with anemia on admission or at discharge [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H459619547"><span class="h1">PLASMA ALDOSTERONE</span><span class="headingEndMark"> — </span>Although the plasma aldosterone concentration is not routinely measured in patients with acute MI, there is evidence that it is a predictor of patient outcomes. The relationship between the plasma aldosterone concentration at the time of presentation of STEMI and subsequent cardiovascular morbidity and mortality was evaluated in an observational study of 356 patients treated with primary percutaneous coronary intervention (PCI) [<a href="#rid48">48</a>]. Patients were divided into four quartiles of plasma aldosterone and evaluated for in-hospital events and six-month mortality. There was a stepwise significant increase in the risk of in-hospital death; HF; ventricular fibrillation or resuscitated cardiac arrest. After adjusting for age, Killip class  (<a class="graphic graphic_table graphicRef65592" href="/z/d/graphic/65592.html" rel="external">table 1</a>) and reperfusion status, compared with patients in the first aldosterone quartile, patients in the highest quartile were at a significantly higher risk of death at six months.</p><p>The adverse outcomes associated with hyperaldosteronism may be explained by at least two mechanisms: Hyperaldosteronism is a secondary event, being a marker of reduced peripheral perfusion, and/or high levels of aldosterone have direct cardiovascular toxicity. Support for the latter hypothesis comes from studies of patients with primary hyperaldosteronism and from the survival benefit associated with aldosterone antagonists in selected patients with HF and MI. (See  <a class="medical medical_review" href="/z/d/html/67.html" rel="external">"Overview of the nonacute management of ST-elevation myocardial infarction", section on 'Discharge medications'</a> and  <a class="medical medical_review" href="/z/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism", section on 'Cardiovascular risk'</a> and  <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Evidence'</a>.)</p><p class="headingAnchor" id="H459619701"><span class="h1">FINDINGS AT THE TIME OF ANGIOGRAPHY AND PCI</span></p><p class="headingAnchor" id="H3496735310"><span class="h2">Coronary artery patency</span><span class="headingEndMark"> — </span>A patent-infarct-related artery, established as early as possible after coronary artery occlusion, is associated with lower mortality in patients who have received fibrinolytic therapy [<a href="#rid49">49-58</a>]. Similarly, spontaneous reperfusion is associated with lower mortality [<a href="#rid59">59,60</a>], while persistent occlusion of the infarct-related artery is associated with increased morbidity and mortality.</p><p class="headingAnchor" id="H459619639"><span class="h2">Abnormal myocardial perfusion</span><span class="headingEndMark"> — </span>Angiographic (myocardial blush or perfusion grade and TIMI frame count) signs of abnormal myocardial perfusion predict a worse outcome after both fibrinolysis and primary percutaneous coronary intervention (PCI). The definition of the angiographic variables and their predictive value are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/80.html" rel="external">"Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"</a> and  <a class="medical medical_review" href="/z/d/html/91.html" rel="external">"Diagnosis and management of failed fibrinolysis or threatened reocclusion in acute ST-elevation myocardial infarction", section on 'Primary failure'</a>.)</p><p class="headingAnchor" id="H459619646"><span class="h2">Age of aspirated thrombus</span><span class="headingEndMark"> — </span>Thrombus aspiration is performed in many patients who undergo primary PCI for STEMI. The short-term outcomes of thrombus aspiration and the possible prognostic importance of thrombus age are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/81.html" rel="external">"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST-elevation myocardial infarction", section on 'Thrombectomy'</a>.)</p><p class="headingAnchor" id="H3363686857"><span class="h2">"Wrap around" LAD</span><span class="headingEndMark"> — </span>An infarct-related, left anterior descending coronary artery that wraps around the LV apex is a predictor of adverse clinical outcomes at three years in patients with STEMI [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H9360187"><span class="h1">PSYCHOSOCIAL FACTORS</span><span class="headingEndMark"> — </span>The role of psychosocial factors as triggers for and determinants of outcome with acute MI are discussed separately. Specifically, psychologic stress has been associated with both stress (Takotsubo) cardiomyopathy and spontaneous coronary artery dissection. (See  <a class="medical medical_review" href="/z/d/html/4854.html" rel="external">"Psychosocial factors in acute coronary syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/3494.html" rel="external">"Clinical manifestations and diagnosis of stress (takotsubo) cardiomyopathy", section on 'Role of catecholamines'</a> and  <a class="medical medical_review" href="/z/d/html/97665.html" rel="external">"Spontaneous coronary artery dissection", section on 'Triggers'</a>.)</p><p class="headingAnchor" id="H230667134"><span class="h1">SOCIOECONOMIC STATUS</span><span class="headingEndMark"> — </span>Socioeconomic Status (SES) has been investigated as a determinant of outcomes in patients with STEMI. Among more than 5000 Australian registry participants, lower SES was associated with greater prevalence of diabetes mellitus, smoking, and initial presentation to non-percutaneous coronary intervention (PCI)-capable hospitals, leading to a slightly greater time to reperfusion and less frequent drug-eluting stents during the interval of 2005 to 2015. Lower SES was not associated with worse survival 12 months after PCI [<a href="#rid62">62</a>]. In another study, STEMI patients in the lower SES groups were more likely to be smokers, have diabetes, and to have previously had coronary heart disease, but no significant differences in survival with 30-day, one-, or three-year follow-up were observed [<a href="#rid63">63</a>]. In a third study of more than 6.6 million United States patients with MI in the National Inpatient Sample study from 2004 to 2014, STEMI patients in the lowest SES quartile, estimated by residential income geocoding, were slightly less likely to undergo coronary angiography or PCI and experienced mildly greater risk for clinical atherosclerotic cardiovascular disease outcomes [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H1306357907"><span class="h1">REHOSPITALIZATION WITHIN 30 DAYS</span><span class="headingEndMark"> — </span>For patients with acute MI, the rehospitalization rate within 30 days ranges between 10 and 30 percent and readmission often occurs within two to four days [<a href="#rid65">65-67</a>]. Women have a higher rate than men. Poor baseline quality of life and depression, as well as longer index hospital length of stay, are predictive of rehospitalization.</p><p class="headingAnchor" id="H459619502"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with an acute coronary syndrome should undergo risk stratification to predict those who are at high risk for short- and long-term adverse outcomes. Risk stratification should begin soon after hospitalization. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although many risk factors for adverse events after ST-elevation myocardial infarction (STEMI) have been identified, only a few are used in the risk prediction models:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who receive fibrinolytic therapy, the most important risk factors are age &gt;65 years, Killip class II to IV, blood pressure &lt;100 mmHg or hypotension, heart rate &gt;100 beats per minute (bpm), elevated serum creatinine, anterior myocardial infarction (MI), and cardiac arrest during presentation. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction", section on 'Early risk stratification'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who receive primary percutaneous coronary intervention (PCI), the most important risk factors are reduced left ventricular (LV) ejection fraction, Killip class, elevated serum creatinine, anemia, reduced TIMI flow grade, triple vessel disease, and age &gt;65 years. (See  <a class="medical medical_review" href="/z/d/html/78.html" rel="external">"Risk stratification after acute ST-elevation myocardial infarction", section on 'Late risk stratification'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Canto JG, Kiefe CI, Rogers WJ, et al. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA 2011; 306:2120.</a></li><li><a class="nounderline abstract_t">Shlipak MG, Heidenreich PA, Noguchi H, et al. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137:555.</a></li><li><a class="nounderline abstract_t">Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285.</a></li><li><a class="nounderline abstract_t">Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137:563.</a></li><li><a class="nounderline abstract_t">McCullough PA, Nowak RM, Foreback C, et al. Emergency evaluation of chest pain in patients with advanced kidney disease. Arch Intern Med 2002; 162:2464.</a></li><li><a class="nounderline abstract_t">Narins CR, Zareba W, Moss AJ, et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 2004; 164:440.</a></li><li><a class="nounderline abstract_t">Bucholz EM, Krumholz HA, Krumholz HM. Underweight, Markers of Cachexia, and Mortality in Acute Myocardial Infarction: A Prospective Cohort Study of Elderly Medicare Beneficiaries. PLoS Med 2016; 13:e1001998.</a></li><li><a class="nounderline abstract_t">Becker RC, Burns M, Gore JM, et al. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. Am Heart J 1998; 135:786.</a></li><li><a class="nounderline abstract_t">Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20:457.</a></li><li><a class="nounderline abstract_t">Wu AH, Parsons L, Every NR, et al. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 2002; 40:1389.</a></li><li><a class="nounderline abstract_t">Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004; 109:494.</a></li><li><a class="nounderline abstract_t">Califf RM, Pieper KS, Lee KL, et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 2000; 101:2231.</a></li><li><a class="nounderline abstract_t">Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102:2031.</a></li><li><a class="nounderline abstract_t">De Luca G, Suryapranata H, van 't Hof AW, et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation 2004; 109:2737.</a></li><li><a class="nounderline abstract_t">Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005; 45:1397.</a></li><li><a class="nounderline abstract_t">DeGeare VS, Boura JA, Grines LL, et al. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2001; 87:1035.</a></li><li><a class="nounderline abstract_t">De Luca G, van 't Hof AW, de Boer MJ, et al. Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure. Circulation 2004; 109:958.</a></li><li><a class="nounderline abstract_t">Crimm A, Severance HW Jr, Coffey K, et al. Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. Am J Med 1984; 76:983.</a></li><li><a class="nounderline abstract_t">Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86:527.</a></li><li><a class="nounderline abstract_t">Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation 2011; 123:2094.</a></li><li><a class="nounderline abstract_t">Poçi D, Hartford M, Karlsson T, et al. Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation. Chest 2012; 141:1431.</a></li><li><a class="nounderline abstract_t">Betriu A, Califf RM, Bosch X, et al. Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31:94.</a></li><li><a class="nounderline abstract_t">Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.</a></li><li><a class="nounderline abstract_t">GISSI-3 APPI Study Group. Early and six-month outcome in patients with angina pectoris early after acute myocardial infarction (the GISSI-3 APPI [angina precoce post-infarto] study). Am J Cardiol 1996; 78:1191.</a></li><li><a class="nounderline abstract_t">Gottlieb SO, Gottlieb SH, Achuff SC, et al. Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients. JAMA 1988; 259:1030.</a></li><li><a class="nounderline abstract_t">Deedwania PC. Asymptomatic ischemia during predischarge Holter monitoring predicts poor prognosis in the postinfarction period. Am J Cardiol 1993; 71:859.</a></li><li><a class="nounderline abstract_t">Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 140:917.</a></li><li><a class="nounderline abstract_t">Kanna M, Nonogi H, Sumida H, et al. Usefulness of serum troponin T levels on day three or four in predicting survival after acute myocardial infarction. Am J Cardiol 2001; 87:294.</a></li><li><a class="nounderline abstract_t">Giannitsis E, Müller-Bardorff M, Lehrke S, et al. Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 2001; 104:630.</a></li><li><a class="nounderline abstract_t">Ohman EM, Armstrong PW, White HD, et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999; 84:1281.</a></li><li><a class="nounderline abstract_t">Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93:1963.</a></li><li><a class="nounderline abstract_t">Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97:1921.</a></li><li><a class="nounderline abstract_t">Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106:2913.</a></li><li><a class="nounderline abstract_t">Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107:2786.</a></li><li><a class="nounderline abstract_t">Tapanainen JM, Lindgren KS, Mäkikallio TH, et al. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2004; 43:757.</a></li><li><a class="nounderline abstract_t">Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004; 44:335.</a></li><li><a class="nounderline abstract_t">Khan SQ, Quinn P, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart 2008; 94:40.</a></li><li><a class="nounderline abstract_t">Goyal A, Spertus JA, Gosch K, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA 2012; 307:157.</a></li><li><a class="nounderline abstract_t">Grodzinsky A, Goyal A, Gosch K, et al. Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. Am J Med 2016; 129:858.</a></li><li><a class="nounderline abstract_t">Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004; 44:1945.</a></li><li><a class="nounderline abstract_t">Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000; 102:2329.</a></li><li><a class="nounderline abstract_t">Cannon CP, McCabe CH, Wilcox RG, et al. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol 2001; 87:636.</a></li><li><a class="nounderline abstract_t">Barron HV, Harr SD, Radford MJ, et al. The association between white blood cell count and acute myocardial infarction mortality in patients &gt; or =65 years of age: findings from the cooperative cardiovascular project. J Am Coll Cardiol 2001; 38:1654.</a></li><li><a class="nounderline abstract_t">Grau AJ, Boddy AW, Dukovic DA, et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004; 35:1147.</a></li><li><a class="nounderline abstract_t">Patel MR, Mahaffey KW, Armstrong PW, et al. Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). Am J Cardiol 2005; 95:614.</a></li><li><a class="nounderline abstract_t">Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111:2042.</a></li><li><a class="nounderline abstract_t">Aronson D, Suleiman M, Agmon Y, et al. Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction. Eur Heart J 2007; 28:1289.</a></li><li><a class="nounderline abstract_t">Beygui F, Collet JP, Benoliel JJ, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006; 114:2604.</a></li><li><a class="nounderline abstract_t">Kennedy JW, Ritchie JL, Davis KB, et al. The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report. N Engl J Med 1985; 312:1073.</a></li><li><a class="nounderline abstract_t">Vogt A, von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. J Am Coll Cardiol 1993; 21:1391.</a></li><li><a class="nounderline abstract_t">Anderson JL, Karagounis LA, Becker LC, et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993; 87:1829.</a></li><li><a class="nounderline abstract_t">Cigarroa RG, Lange RA, Hillis LD. Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow. Am J Cardiol 1989; 64:155.</a></li><li><a class="nounderline abstract_t">McCully RB, elZeky F, vanderZwaag R, et al. Impact of patency of the left anterior descending coronary artery on long-term survival. Am J Cardiol 1995; 76:250.</a></li><li><a class="nounderline abstract_t">Schröder R, Neuhaus KL, Linderer T, et al. Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study). Am J Cardiol 1989; 64:878.</a></li><li><a class="nounderline abstract_t">Galvani M, Ottani F, Ferrini D, et al. Patency of the infarct-related artery and left ventricular function as the major determinants of survival after Q-wave acute myocardial infarction. Am J Cardiol 1993; 71:1.</a></li><li><a class="nounderline abstract_t">White HD, Cross DB, Elliott JM, et al. Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction. Circulation 1994; 89:61.</a></li><li><a class="nounderline abstract_t">Lamas GA, Flaker GC, Mitchell G, et al. Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators. Circulation 1995; 92:1101.</a></li><li><a class="nounderline abstract_t">Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97:1549.</a></li><li><a class="nounderline abstract_t">Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001; 104:636.</a></li><li><a class="nounderline abstract_t">De Luca G, Ernst N, Zijlstra F, et al. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2004; 43:1363.</a></li><li><a class="nounderline abstract_t">Kobayashi N, Maehara A, Brener SJ, et al. Usefulness of the Left Anterior Descending Coronary Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol 2015; 116:1658.</a></li><li><a class="nounderline abstract_t">Biswas S, Andrianopoulos N, Duffy SJ, et al. Impact of Socioeconomic Status on Clinical Outcomes in Patients With ST-Segment-Elevation Myocardial Infarction. Circ Cardiovasc Qual Outcomes 2019; 12:e004979.</a></li><li><a class="nounderline abstract_t">Steele L, Palmer J, Lloyd A, et al. Impact of socioeconomic status on survival following ST-elevation myocardial infarction in a universal healthcare system. Int J Cardiol 2019; 276:26.</a></li><li><a class="nounderline abstract_t">Matetic A, Bharadwaj A, Mohamed MO, et al. Socioeconomic Status and Differences in the Management and Outcomes of 6.6 Million US Patients With Acute Myocardial Infarction. Am J Cardiol 2020; 129:10.</a></li><li><a class="nounderline abstract_t">Tisminetzky M, McManus DD, Erskine N, et al. Thirty-day Hospital Readmissions in Patients with Non-ST-segment Elevation Acute Myocardial Infarction. Am J Med 2015; 128:760.</a></li><li><a class="nounderline abstract_t">Dreyer RP, Ranasinghe I, Wang Y, et al. Sex Differences in the Rate, Timing, and Principal Diagnoses of 30-Day Readmissions in Younger Patients with Acute Myocardial Infarction. Circulation 2015; 132:158.</a></li><li><a class="nounderline abstract_t">Hess CN, Wang TY, McCoy LA, et al. Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. Circulation 2016; 133:493.</a></li></ol></div><div id="topicVersionRevision">Topic 88759 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22089719" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353942" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15385655" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12353943" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acute myocardial infarction and renal dysfunction: a high-risk combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12437406" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Emergency evaluation of chest pain in patients with advanced kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14980996" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27093615" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Underweight, Markers of Cachexia, and Mortality in Acute Myocardial Infarction: A Prospective Cohort Study of Elderly Medicare Beneficiaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588407" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6059183" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12392826" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14744970" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10811588" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044416" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15159293" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15862409" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11348598" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981008" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Impaired myocardial perfusion is a major explanation of the poor outcome observed in patients undergoing primary angioplasty for ST-segment-elevation myocardial infarction and signs of heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6731469" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11602545" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536994" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Atrial fibrillation and death after myocardial infarction: a community study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22016485" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke in patients with and without atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9426024" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9799205" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960573" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Early and six-month outcome in patients with angina pectoris early after acute myocardial infarction (the GISSI-3 APPI [angina precoce post-infarto] study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3339800" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8456768" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Asymptomatic ischemia during predischarge Holter monitoring predicts poor prognosis in the postinfarction period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11099996" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11165963" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Usefulness of serum troponin T levels on day three or four in predicting survival after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11489766" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10614791" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640969" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9609085" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460871" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12771003" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14998613" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15261928" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17488769" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22235086" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Serum potassium levels and mortality in acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27060233" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15542275" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Leukocyte count and coronary heart disease: implications for risk assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11067784" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11230853" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704377" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The association between white blood cell count and acute myocardial infarction mortality in patients&gt;or =65 years of age: findings from the cooperative cardiovascular project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15017013" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Leukocyte count as an independent predictor of recurrent ischemic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15721102" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824203" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Association of hemoglobin levels with clinical outcomes in acute coronary syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17363447" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17116769" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3982468" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. A 12-month follow-up report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8473646" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504495" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2741824" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7618618" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impact of patency of the left anterior descending coronary artery on long-term survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2801555" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact of late coronary artery reperfusion on left ventricular function one month after acute myocardial infarction (results from the ISAM study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420223" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Patency of the infarct-related artery and left ventricular function as the major determinants of survival after Q-wave acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8281696" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7648653" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of infarct artery patency on prognosis after acute myocardial infarction. The Survival and Ventricular Enlargement Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9593559" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11489767" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15093868" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26433272" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Usefulness of the Left Anterior Descending Coronary Artery Wrapping Around the Left Ventricular Apex to Predict Adverse Clinical Outcomes in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30606051" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Impact of Socioeconomic Status on Clinical Outcomes in Patients With ST-Segment-Elevation Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30514579" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Impact of socioeconomic status on survival following ST-elevation myocardial infarction in a universal healthcare system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32576369" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Socioeconomic Status and Differences in the Management and Outcomes of 6.6 Million US Patients With Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25660250" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Thirty-day Hospital Readmissions in Patients with Non-ST-segment Elevation Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26085455" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sex Differences in the Rate, Timing, and Principal Diagnoses of 30-Day Readmissions in Younger Patients with Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26680241" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
